Nanotools Bioscience

Biotech · Private

Graphene-mediated optical stimulation (GraMOS) platform for non-genetic neural stimulation in drug screening assays

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Biotech
Total capital
$2.2M
Federal grants
$2.2M
7 awards · 2017–2021
Rank in peer group#11 of 17
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20172018201920202021FEDERAL ↑EQUITY ↓Cumulative $2.2M$325K$325K$325K$325K$350K$350K
20172018201920202021FEDERAL ↑EQUITY ↓Cumulative $2.2M$350K$350K

Latest events

  • Federal grantHealth and Human S · Phase I · Non-genetic optical stimulation platform for the next-generation neuroscience drug discovery assays$350K
  • Federal grantHealth and Human S · Phase I · Non-genetic optical stimulation platform for the next-generation neuroscience drug discovery assays$350K
  • Federal grantHealth and Human S · Phase I · LightKick: Novel bioengineering system for activity-dependent acceleration of functional maturation of human stem cell-derived cardiomyocytes$325K
  • Federal grantHealth and Human S · Phase I · LightKick: Novel bioengineering system for activity-dependent acceleration of functional maturation of human stem cell-derived cardiomyocytes$325K
  • Federal grantNSF · Phase I · SBIR Phase I: Optoelectronic Microplates: Disruptive Optical Stimulation Technology for Drug Discovery Screening Assays$225K
  • Federal grantHealth and Human S · Phase I · Novel nanotechnology based optical stimulation platform for predictive cardiotoxicity assessment$325K
  • Federal grantHealth and Human S · Phase I · Novel nanotechnology-based optical stimulation platform for predictive cardiotoxicity assessment$325K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 17 peers

Line = median

Biotech · Device

  • Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • NANOTOOLS BIOSCIENCE LLCShares a founder: ELENA MOLOKANOVA
  • NEURANO BIOSCIENCE LLCShares a founder: ELENA MOLOKANOVA
  • FluidForm Bio, Inc.Similar federal contract value in Biotech · null in contracts
  • ANTICANCER, INC.Similar federal contract value in Biotech · null in contracts
  • PHARMATROPHIX INCSimilar federal contract value in Biotech · null in contracts
  • VilyaSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .